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A key step in angiogenesis is the upregulation of growth factor receptors on endothelial cells. Here, we dem-
onstrate that a small regulatory microRNA, miR-296, has a major role in this process. Glioma cells and angio-
genic growth factors elevate the level of miR-296 in primary human brain microvascular endothelial cells in
culture. The miR-296 level is also elevated in primary tumor endothelial cells isolated from human brain tu-
mors compared to normal brain endothelial cells. Growth factor-induced miR-296 contributes significantly
to angiogenesis by directly targeting the hepatocyte growth factor-regulated tyrosine kinase substrate
(HGS) mRNA, leading to decreased levels of HGS and thereby reducing HGS-mediated degradation of the
growth factor receptors VEGFR2 and PDGFRb. Furthermore, inhibition of miR-296 with antagomirs reduces
angiogenesis in tumor xenografts in vivo.
INTRODUCTION
Angiogenesis is the formation of new blood vessels during
growth and development as well as in disease-related processes
like tumor growth, wound healing, and restoring blood flow to tis-
sues after injury (Folkman, 2007). De novo angiogenesis is a crit-
ical factor in cancer. For instance, malignant brain tumors are
characterized by a marked increase in blood vessel formation,
with tumor vessels having abnormal morphology that serves as
a key feature in tumor grading (Brem et al., 1972; Folkerth,
2000). Increasing awareness of the importance of the vascula-
ture in tumors has led to a focus on this as a therapeutic target
(Kerbel and Folkman, 2002). The state of angiogenesis is a bal-
ance between pro- and antiangiogenic molecules, with a bias
toward the proangiogenic mode (Jain, 2005). A common feature
of angiogenic blood vessels is the high expression of proangio-
genic growth factor receptors, such as platelet-derived growth
factor receptor (PDGFR) and vascular endothelial growth factor
receptor (VEGFR), which are targets of antiangiogenic therapies
(Batchelor et al., 2007; Shih and Holland, 2006). Further under-
standing of the orchestration of this angiogenic switch should
help in the development of strategies to harness the dynamics
of blood vessel formation in human health and disease. Recently,
the discovery of microRNAs (miRNAs) has increased our knowl-
edge regarding the complex control of gene expression. miRNAs
comprise a large group of endogenous noncoding RNAs that can
block mRNA translation and/or negatively regulate its stability
(Ambros, 2004). At this time, over 500 different miRNAs have
SIGNIFICANCE
The formation of new blood vessels by angiogenesis is essential for normal functions and is involved in many disease states,
including cancer. Control of the angiogenic switch in endothelial cells involves changes in levels of pro- and antiangiogenic
molecules acting in concert. Here, we show that glioma- or growth factor-mediated induction of miR-296 in endothelial cells
results in increased levels of proangiogenic growth factor receptors. These results indicate that miR-296, belonging to the
family of ‘‘angiomirs,’’ is functionally linked to the angiogenic phenotype and therefore provide new insights into the role of
miRNA regulation in neovascularization. Further, manipulation of miR-296 levels may prove therapeutic in the large number
of diseases wherein angiogenesis is a critical component.382 Cancer Cell 14, 382–393, November 4, 2008 ª2008 Elsevier Inc.
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miR-296 Modulation of Growth Factor ReceptorsFigure 1. Glioma-Induced Dysregulation of miRNAs in Human Brain Endothelial Cells
(A) Primary human brain microvascular endothelial cells (HBMVECs) were cultured in the absence (left) or presence (right) of human U87-CFP glioma cells. Images
were produced using a combination of light and fluorescence microscopy. Scale bar = 100 mm.
(B) Array hybridization analysis of miRNAs extracted from CD31+ cells sorted from HBMVECs cultured without (upper array) or with (lower array) U87-CFP glioma
cells for 24 hr. The density of the hybridization signals (black spots) reflects the relative expression level of particular miRNAs. Red circles indicate miRNAs that
were significantly altered by coculture with glioma cells.
(C) A list of significantly decreased (fold change < 0.5) or increased (fold change > 1.9) miRNAs in HBMVECs exposed to U87-CFP glioma cells.
(D) Overexpression of miR-296 was confirmed by qRT-PCR analysis. RNA extracted from CD31+ HBMVECs cultured in the absence or presence of U87 glioma
cells was analyzed by qRT-PCR. The data were normalized to the level of GAPDH mRNA in each sample.
(E) HBMVECs were cultured in the presence or absence of U87 glioma cells, isolated using CD31 beads, and subjected to miR-296 qRT-PCR. Alternatively,
HBMVECs were cultured in various culture media and subjected to miR-296 qRT-PCR. miR-296 levels were normalized to EBM (CD31).
Error bars indicate SD. *p < 0.05, ***p < 0.001 by t test.been identified in human cells (Griffiths-Jones et al., 2006). Accu-
mulating evidence indicates that regulation of miRNA levels is
very important for proper growth and differentiation of many
cell types and tissues (Bartel, 2004; Kloosterman and Plasterk,
2006; Krichevsky et al., 2003). It is also becoming clear that
deregulated miRNA expression is a common feature of many
human diseases, especially specific forms of cancer (Calin and
Croce, 2006; Esquela-Kerscher and Slack, 2006; Ruvkun,
2006). Here, we aimed at identifying miRNAs that are critical to
tumor angiogenesis.
RESULTS
Since glioma cells have a high capacity to induce angiogenesis
(Brem et al., 1972; Folkerth, 2000), we used them as a means
to stimulate this process in normal endothelial cells in a coculture
system. Primary human microvascular endothelial cells isolated
from normal human brain (HBMVECs; Cell Systems, ACBRI-376)
were cultured in the presence or absence of human U87 glioma
cells expressing cerulean fluorescent protein (CFP) in endothelial
basal medium lacking additional angiogenic factors (EBM; Cam-
brex). Elongation of the endothelial cells was induced by the
cancer cells as a first step in the activation of angiogenesis, as
described previously (Khodarev et al., 2003) (Figure 1A). AfterC24 hr of either culturing the endothelial cells alone or coculturing
them with human U87 glioma cells, the endothelial cells were iso-
lated using CD31 magnetic beads (Dynal Biotech). The purity
(>99%) of the endothelial cell preparation was confirmed by
the absence of glioma cells expressing the CFP marker (data
not shown). Total RNA was isolated from endothelial cells, and
the small RNA fraction was hybridized to miRNA arrays contain-
ing probes for 407 mature miRNAs (as in Krichevsky et al., 2003)
in order to identify differentially expressed miRNAs. Analysis
of array hybridizations revealed 80 miRNAs expressed in
HBMVECs at detectable levels (Figure 1B; see also Figure S1
available online) and confirmed the expression of a number of
previously described miRNAs in endothelial cells (Kuehbacher
et al., 2007; Poliseno et al., 2006; Sua´rez et al., 2007; Tuccoli
et al., 2006). After exposure of HBMVECs to U87 glioma cells,
the expression levels of a number of miRNAs changed signifi-
cantly. This suggests that glioma cells can influence miRNA ex-
pression in endothelial blood vessel cells (Figures 1B and 1C).
Most of the differentially expressed miRNAs were found to be
downregulated. One miRNA, miR-296, was identified and further
confirmed by quantitative RT-PCR (qRT-PCR) analysis to be up-
regulated. We used miR-186 as a control miRNA and GAPDH as
a normalization control, both of which were uniformly expressed
in endothelial cells in the presence or absence of tumor cellsancer Cell 14, 382–393, November 4, 2008 ª2008 Elsevier Inc. 383
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miR-296 Modulation of Growth Factor Receptors(Figure 1D). In this study, we further investigated miR-296 since it
was the only significantly upregulated miRNA in the glioma-
induced endothelial cells.
In order to determine what factors are responsible for the in-
duction of miR-296, HBMVECs were cultured using various con-
ditions, after which RNA was isolated and miR-296 expression
levels were determined. Of note, miR-296 was induced not
only in HBMVECs upon exposure of these cells to U87 glioma
cells but also by culture medium derived from U87 glioma cells
and by EBM supplemented with angiogenic cocktail (EGM, con-
taining hydrocortisone, EGF, FGF, VEGF, IGF, ascorbic acid,
FBS, and heparin; SingleQuots from Cambrex). Similar 2-fold
induction of miR-296 in HBMVECs was achieved by EGM and
glioma cell stimulation. Since U87-conditioned medium and
EGM both contain many growth factors, HBMVECs were also
stimulated with basal medium supplemented with VEGF or EGF,
each of which resulted in significant miR-296 upregulation, in
contrast to exposure to hydrocortisone and heparin, which did
not change levels (Figure 1E).
Since VEGF enhanced miR-296 expression in endothelial
cells, we addressed VEGF function in angiogenesis in endothe-
lial cell culture. First, HBMVECs were cultured in the presence
of different amounts of VEGF in EBM on a Matrigel substrate
to promote tubule formation for 24 hr. A clear dose-response ef-
Figure 2. VEGF-Mediated Induction of Tubule Forma-
tion, Migration, and miR-296 Expression
(A–C) HBMVECs were cultured on Matrigel-coated plates in
basal medium (EBM) only, basal medium supplemented with
a cocktail of angiogenic factors (EGM), or different amounts
of VEGF (A) and analyzed for tubule branching (B) and tubule
length (C) after 24 hr. Scale bar in (A) = 300 mm.
(D) HBMVEC monolayer cultures were scratched and incu-
bated as in (A). Directly after scratching (t = 0) and 24 hr later
(t = 24), images were acquired. Dashed lines indicate the front
of migration. Scale bar = 300 mm.
(E) Quantitation of migration distance using MetaVue software.
(F) HBMVECs were cultured as in (A) for 24 hr, after which
RNA was isolated to determine the levels of miR-296 and
miR-186 expression by qRT-PCR. The data were normalized
to the level of GAPDH mRNA in each sample.
Error bars indicate SD.
fect of VEGF on endothelial tubule formation and
branching was observed (Figures 2A–2C). In order
to determine whether endothelial cell migration
was also affected by VEGF, scratch assays were
performed. HBMVECs were first cultured in EGM,
and a spatula was then used to scratch the mono-
layer, after which the cells were washed and
cultured in EBM containing different amounts of
VEGF, or in EGM, for 24 hr. VEGF significantly
induced the migration of HBMVECs in a dose-
responsive manner (Figures 2D and 2E). To deter-
mine a correlation between VEGF-induced pheno-
type and miR-296 expression, HBMVECs were
cultured for 24 hr in EBM containing different
amounts of VEGF, or in EGM, after which RNA
was isolated and miR-296 expression levels were
determined by qRT-PCR. Notably, 10 ng/ml of
VEGF was sufficient to coordinately upregulate miR-296 levels
and induce endothelial cell migration and tubule formation in
HBMVEC cultures (Figures 2B, 2C, 2E, and 2F).
To address miR-296 function in angiogenesis, we examined
the effects of its inhibition on glioma-induced angiogenesis in
cell culture. In these experiments, HBMVECs were cultured on
Matrigel in EBM alone, in EBM with human glioma cells, or in
EGM. Tubules were visualized by a combination of light and fluo-
rescence microscopy. Endothelial cells were discriminated from
CFP-expressing U87 glioma cells by fluorescence microscopy
(Figure 3A). miR-296 in endothelial cells was blocked by trans-
fecting endothelial cells with a modified antisense miR-296 inhib-
itor (Ambion) prior to mixing the endothelial cells with U87 cells,
with transfection efficiency being >99% as determined by trans-
fection of siRNA-Cy3 (Alnylam) (Figure 3A). Levels of miR-296
decreased 4-fold in HBMVECs in the presence of this inhibitor
as determined by qRT-PCR (Figure 3B). At 48 hr after transfec-
tion of the miR-296 inhibitor or a nonrelated oligonucleotide of
similar chemistry and 24 hr of culturing on Matrigel with or with-
out U87-CFP cells, endothelial cells were analyzed for effects on
tubule length and tubule branching (Figure 3C). Downregulation
of miR-296 resulted in a significant decrease in tubule branching
(Figure 3D) and total tubule length (Figure 3E) in HBMVECs
exposed to an angiogenic cocktail or U87 glioma cells as384 Cancer Cell 14, 382–393, November 4, 2008 ª2008 Elsevier Inc.
Cancer Cell
miR-296 Modulation of Growth Factor Receptorscompared to unexposed cells but had no significant effect on the
viability of endothelial cells (Figure S2). U87 glioma cells induced
tubule elongation to a greater extent than EGM, which may be
due to other glioma cell-induced effects in addition to elevation
of miR-296 (Figure 3E). Similar inhibitory effects on tubule forma-
tion were observed when miR-296 was blocked in human umbil-
ical vein endothelial cells (HUVECs) exposed to an angiogenic
cocktail (Figure S3), suggesting a general miR-296-mediated
angiogenic mechanism operating in endothelial cells of different
origins. In order to determine the effect of miR-296 inhibition on
glioma-induced endothelial cell migration, scratch assays were
performed. HBMVECs were transfected with the miR-296 inhib-
itor or control oligonucleotide. Twenty-four hours after transfec-
tion, a scratch was made in the monolayer of HBMVECs cultured
in U87-conditioned medium. Twenty-four hours after that, the
migration distance was analyzed by light microscopy and
MetaVue software. Downregulation of miR-296 resulted in a sig-
nificant decrease in U87-induced HBMVEC migration (Figures
3F and 3G).
To investigate whether miR-296 acts as a dominant determi-
nant of angiogenesis, miR-296 precursor molecules or control
precursor-like molecules (Ambion) were transfected into
HBMVECs cultured in EBM medium. Transfection efficiency
was >99% as analyzed by fluorescence microscopy using a pre-
cursor control molecule conjugated to a Cy3 fluorophor (Ambion)
(data not shown). Overexpression of miR-296 in cells transfected
with miR-296 precursors was confirmed by qRT-PCR (Figure 3B).
Twenty-four hours after transfection, HBMVECs were plated on
Matrigel in the absence of angiogenic stimuli. Pre-miR-296 stim-
ulated tubule elongation and branching, in contrast to the control
miRNA precursor (Figures 3H–3J). These effects were observed
for up to at least 4 days after transfection of pre-miR-296 mole-
cules into HBMVECs (Figure S4). Together, these data support
a positive regulatory role for miR-296 in the induction of angio-
genesis, i.e., miR-296 inhibition reduces the angiogenic pheno-
type, while miR-296 overexpression increases it.
To identify target genes regulated by miR-296 and involved in
control of angiogenesis,wenextevaluatedtargetscomputationally
Figure 3. Angiogenesis Coculture Assay:
miR-296-Mediated Inhibition and Induction
of Angiogenesis
(A) HBMVECs were cultured on Matrigel-coated
plates in basal medium (EBM) only, in basal
medium supplemented with a cocktail of angio-
genic factors (EGM), or with U87-CFP cells. Trans-
fection efficiency of endothelial cells was deter-
mined (>99%) using siRNA-Cy3 molecules. Scale
bars = 300 mm; monolayer culture scale bar in
lower right panel = 50 mm.
(B) HBMVECs were transfected with anti-miR-296
inhibitor, pre-miR-296, or nonrelated control mole-
cules and cultured in the presence or absence of
U87-CFP cells. Inhibition and overexpression of
miR-296 in CD31+-isolated endothelial cells were
quantified by qRT-PCR.
(C) HBMVECs were transfected with anti-miR-
296 inhibitor or nonrelated control molecules
and analyzed for tubule formation. Scale bars =
300 mm.
(D and E) Tubule formation was evaluated at 48 hr
after transfection, including 24 hr of culturing on
Matrigel, using the imaging program ImageJ. A
significant decrease in tubule branching (D) and
tubule length (E) was observed after transfection
with miR-296 inhibitor.
(F and G) HBMVECs were transfected with anti-
miR-296 inhibitor or nonrelated control molecules
and analyzed for migration capacity (F). Inhibition
of miR-296 resulted in a significant decrease in
migration, as quantified in (G).
(H–J) Overexpression of miR-296 at 24 hr after
transfection of pre-miR-296 molecules resulted
in increased angiogenesis in vitro (H), as quantified
by measuring tubule branching (I) and tubule
length (J). Scale bars in (H) = 300 mm.
Error bars indicate SD. **p < 0.01, ***p < 0.001 by
t test.Cancer Cell 14, 382–393, November 4, 2008 ª2008 Elsevier Inc. 385
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2006; John et al., 2004; Krek et al., 2005; Lewis et al., 2005; Mi-
randa et al., 2006). Interestingly, hepatocyte growth factor-regu-
lated tyrosine kinase substrate (HGS) was one of the highest
scored (according to miRBase, http://microrna.sanger.ac.uk;
Griffiths-Jones et al., 2006) among the predicted miR-296 tar-
gets, with two potential conserved binding sites within its
30UTR (Figure 4A). The HGS protein is involved in the regulation
of levels of growth factor receptors, such as PDGFRb (Takata
et al., 2000) and VEGFR2 (Ewan et al., 2006). Upon ligand stimu-
lation, phosphorylation, ubiquitination, and internalization of
growth factor receptors, HGS mediates the sorting of these
ligand/receptor complexes to lysosomes, where they are de-
graded (Bache et al., 2003; Ewan et al., 2006; Haglund et al.,
2003; Raiborg et al., 2002; Stern et al., 2007; Takata et al.,
2000). Elevated levels of growth factor receptors on the surface
of endothelial cells, usually observed during tumor-induced an-
giogenesis, suggest a diminished role for HGS. In fact, silencing
of HGS by siRNAs results in decreased degradation of growth
factor receptors and hence their increased cellular levels (Bache
et al., 2003; Stern et al., 2007). We hypothesized that miR-296
might downregulate synthesis of HGS by directly binding to sites
within the 30UTR of its message, thereby facilitating accumulation
of angiogenic growth factor receptors. To test this hypothesis, we
constructed luciferase reporter vectors encoding the complete
wild-type 30UTR of the HGS mRNA (HGS WT) as well as parallel
control vectors containing mismatches in the predicted miR-
296 binding sites (HGS mut1 and HGS mut2) or a luciferase vector
containing no HGS UTR (MCS) and transfected these vectors into
miR-296-expressing HEK293T cells (Miranda et al., 2006). Trans-
fection of the HGS WT plasmid resulted in a decrease in luciferase
expression (mock and control inhibitor) as compared to transfec-
tion of the MCS control (same conditions), supporting a negative
effect of the endogenous miR-296 molecules on the HGS 30UTR
(Figure 4B). Blockage of endogenous miR-296 molecules using
an antisense inhibitor (Ambion) resulted in a significant increase
Figure 4. HGS Is a Direct Target of miR-296
(A) Alignment of potential miR-296 binding sites
in the 30UTR of the HGS mRNA of different
species.
(B) pMir-Report vectors containing no 30UTR
(MCS) or containing the 30UTR of the wild-type
HGS mRNA (HGS WT) or mutated miR-296
binding sites (HGS mut1 and HGS mut2) and
miR-296 or control inhibitors were cotransfected
into HEK293T cells. The inhibition of miR-296
by the antisense inhibitors resulted in a significant
increase in luciferase signals of HGS WT-
and HGS mut2- but not HGS mut1-transfected
cells.
(C) Western blot analysis of HGS, PDGFRb, and
VEGFR2 expression in HBMVECs cultured in
basal medium (EBM) or HBMVECs stimulated by
EGM or U87-conditioned medium. HGS expres-
sion decreased upon stimulation of HBMVECs,
and PDGFRb and VEGFR2 increased. Upon inhibi-
tion of miR-296 with anti-miR-296 molecules by
transfection of HBMVECs stimulated by EGM or
U87-conditioned medium, HGS expression in-
creased, and PDGFRb and VEGFR2 decreased.
Relative blot intensities were quantified by using
ImageQuant; densitometric values normalized to
b-actin are indicated.
(D) HGS, PDGFRb, and VEGFR2 expression levels
under normal and angiogenic conditions. Repre-
sentative images of HBMVEC immunostaining for
HGS, PDGFRb, and VEGFR2 under normal (EBM)
and angiogenic (EGM) conditions are shown.
Scale bar = 20 mm.
(E) Quantification of HGS, PDGFRb, and VEGFR2
immunostaining levels as represented in (D). Fluo-
rescence signals were quantified using MetaVue
software by analyzing at least 20 random cells
per sample.
(F and G) Silencing of HGS by siRNAs leads to
increased HBMVEC tubule formation on Matrigel
(F), as quantified in (G). Scale bar in (F) = 300 mm.
Error bars indicate SD. **p < 0.01, ***p < 0.001 by
t test.386 Cancer Cell 14, 382–393, November 4, 2008 ª2008 Elsevier Inc.
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predicted miR-296 binding site 1 (nt 114–134; HGS mut1, Figures
4A and 4B) caused a loss of luciferase sensitivity to miR-296 inhi-
bition as compared to HGS WT, while HGS mut2 with a mutation
in miR-296 binding site 2 (nt 352–372) did not. These experiments
validated the regulatory potential of miR-296 via binding site 1,
which has a better predicted base-pairing and is more evolution-
arily conserved relative to binding site 2 within the HGS 30UTR.
In order to confirm miR-296-mediated modulation of endoge-
nous HGS in endothelial cells, HBMVECs were transfected with
miR-296 inhibitor or control molecules and cultured in EGM or
U87-conditioned medium. After 48 hr, the cell lysates were ana-
lyzed for HGS expression levels by western blotting. Inhibition of
miR-296 resulted in increased levels of HGS (Figure 4C). To de-
termine whether HGS protein levels were reduced in angiogenic
endothelial cells, HBMVECs were cultured in EBM, EGM, or U87-
conditioned medium. After 24 hr, HGS, PDGFRb, and VEGFR2
protein expression levels were determined by western blotting
and normalized to b-actin levels. HBMVECs cultured in the
angiogenesis-inducing (and miR-296-inducing) EGM or U87-
conditioned medium exhibited decreased HGS expression
levels and increased PDGFRb and VEGFR2 expression levels
(Figure 4C). In parallel, HGS as well as PDGFRb and VEGFR2
protein expression levels were determined under normal (EBM)
and angiogenic (EGM) conditions by immunostaining. Immunos-
taining (Figure 4D) and quantitation of the fluorescence intensi-
ties (Figure 4E) showed that the HGS protein level was
decreased at least 2-fold by angiogenic factors, whereas the
PDGFRb and VEGFR2 protein levels were increased about
Figure 5. miR-296 Affects HGS-Modulated
PDGFRb and VEGFR2 Expression
(A) HGS immunostaining of HBMVECs after treat-
ment with miR-296 inhibitors, anti-HGS siRNAs,
and pre-miR-296 molecules. Scale bars = 20 mm.
(B) Immunostaining of PDGFRb and VEGFR2 48 hr
after transfection shows that transfection of pre-
miR-296 molecules, as well as anti-HGS siRNAs,
results in increased PDGFRb and VEGFR2 expres-
sion in HBMVECs. Scale bars = 20 mm.
(C) Western blot analysis of HGS, PDGFRb, and
VEGFR2 expression in HBMVECs upon silencing
of HGS by HGS siRNA or pre-miR-296. Relative
blot intensities were quantitated by using Image-
Quant; the densitometric values are indicated.
(D) Quantification of HGS immunostaining levels,
as represented in (A).
(E) Increased cellular levels of immunoreactive
PDGFRb and VEGFR2 as seen in (B) were quanti-
fied using MetaVue software by analyzing at least
20 random cells per sample.
Error bars indicate SD. **p < 0.01, ***p < 0.001 by
t test.
3-fold. These results show that HGS is
downregulated under angiogenic condi-
tions (in which miR-296 is upregulated),
with this reduction being prevented by
blocking miR-296, and with HGS expres-
sion levels being inversely correlated with
PDGFRb and VEGFR2 levels. To further
confirm the functional effect of HGS on angiogenesis, HGS siR-
NAs (QIAGEN) or control siRNAs were transfected in HBMVECs.
After 24 hr, the transfected HBMVECs were cultured in EBM on
Matrigel. Silencing of HGS resulted in increased tubule formation
and branching (Figures 4F and 4G), supporting critical involve-
ment of HGS in the angiogenic process.
Importantly, antisense inhibition of miR-296 resulted in a mod-
erate but significant increase in levels of endogenous HGS in
HBMVECs, and this effect was abolished by cotransfection
with a siRNA directed against HGS as shown by immunofluores-
cence visualization (Figure 5A) and quantification of average
fluorescence intensities (Figure 5D). In addition, overexpression
of miR-296 resulted in moderate but also significant downregu-
lation of HGS expression (Figures 5A and 5D). The knockdown of
HGS by siRNA or pre-miR-296 was confirmed by western blots
(Figure 5C). Notably, when HGS levels were decreased by either
siRNA or pre-miR-296 transfection, a significant increase in
PDGFRb and VEGFR2 protein levels was observed by immuno-
fluorescence staining (Figures 5B and 5E) and confirmed by
western blots (Figure 5C), consistent with downregulation of
HGS by miR-296, which in turn reduces degradation of the
growth factor receptors. Both down- and upregulation of miR-
296 appear to be physiologically relevant, since they affected
the levels of downstream proteins (HGS, VEGFR2, and PDGFRb)
within the physiologically relevant range observed in angiogenic
versus nonangiogenic conditions.
In order to confirm that HGS-regulated growth factor re-
ceptors are functional in glioma-induced angiogenesis, VEGFR2
receptor antibody blocking experiments were performed.Cancer Cell 14, 382–393, November 4, 2008 ª2008 Elsevier Inc. 387
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24 hr, the HBMVECs were transferred onto Matrigel and cultured
in U87-conditioned medium in the presence or absence of
VEGFR2-blocking antibody (1mg/ml). After 24 hr, a significant de-
crease in tubule length and branching was observed in the pres-
ence, as compared to the absence, of these antibodies (Figures
6A and 6B). In addition, scratch motility assays were performed
using HBMVECs cultured in the presence or absence of
VEGFR2-blocking antibody. After 24 hr, a significant reduction
in the migration distance was observed upon incubation of the
HBMVECs in the presence of VEGFR2 antibody (Figures 6C
and 6D). These results indicate that functional VEGFR2 expres-
Figure 6. Blocking of VEGFR2 Reduces Angiogenesis
In Vitro
(A) HBMVECs were stimulated using U87-conditioned medium
and cultured on Matrigel-coated plates in the presence or
absence of VEGFR2-blocking antibody. Scale bar = 300 mm.
(B) After 24 hr, VEGFR2 blocking significantly reduced tubule
branching and tubule length.
(C and D) HBMVECs were cultured in a monolayer, scratched,
and incubated in the presence or absence of VEGFR2-block-
ing antibody for 24 hr (C). VEGFR2 blocking resulted in a
significant decrease in HBMVEC migration, as quantified in
(D). Scale bar in (C) = 300 mm.
Error bars indicate SD. ***p < 0.001 by t test.
Figure 7. In Vivo Analysis of miR-296 Inhibition of Tumor Neovascularization
(A) Mice with subcutaneous U87 tumors (n = 6) were injected intravenously with miR-296 antagomirs or mismatch control antagomirs. Four days later, the same
mice were injected with AngioSense 750, and tumor vasculature was analyzed by fluorescence-mediated tomography (FMT). Planar (top) and 3D FMT (bottom)
images are displayed in which the fluorescence signals are superimposed with the grayscale planar excitation light image of the mouse. RFI, relative fluorescence
intensity.
(B) Quantitation of the mean fluorescence intensity measurements from tumors in (A) using OsiriX. Error bars indicate SD. *p < 0.05 by t test.
(C) Transverse T1-weighted magnetic resonance (MR) images (4.7T) acquired to show the tumor volume in (A). White arrows indicate tumor mass.
sion contributes to the angiogenic phenotype of
HBMVECs stimulated by U87-conditioned medium.
To analyze whether miR-296 affects glioma
angiogenesis in vivo, a synthetic cholesterol-conju-
gated antagomir-296 antisense oligonucleotide
was designed. U87 glioma cells were injected in the back flanks
of nude mice. After 7 days of tumor growth, antagomir-296 or
mismatch control antagomir was injected intravenously into
these mice (100 ml of a 20 mg/ml stock diluted in PBS). At
4 days after injection of the antagomirs, AngioSense 750 (VisEn
Medical) was injected intravenously in order to quantify neovas-
cularization by fluorescence-mediated tomography (Montet
et al., 2007). The mice injected with antagomir-296 showed a sig-
nificant decrease in mean fluorescence intensity in their tumors
as compared to the mice injected with the mismatch control (Fig-
ures 7A and 7B). T1-weighted magnetic resonance (MR) images
were also acquired to show the tumor volume (Figure 7C). These388 Cancer Cell 14, 382–393, November 4, 2008 ª2008 Elsevier Inc.
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miR-296 Modulation of Growth Factor ReceptorsFigure 8. Analysis of Expression of miR-296 and Its Targets in Tumor Endothelial Cells Isolated from Human Gliomas
(A) RNA was isolated from primary endothelial cell cultures (passage 0) prepared from normal human brain (NNB; n = 3), grade II astrocytomas (n = 3), and grade
IV glioblastoma multiforme (n = 3).
(B) RNA extracted from individual tumor endothelial samples was analyzed by qRT-PCR for expression levels of miR-296 and miR-186. All values were normalized
to GAPDH mRNA levels in the same samples.
(C) Immunohistochemical staining of brain blood vessels indicates increased and morphologically abnormal tumor blood vessels as well as differential HGS,
PDGFRb, and VEGFR2 expression in nonneoplastic brain (NNB) and malignant glioma (GBM). Scale bar = 100 mm.
(D) RNA extracted from individual tumor endothelial samples was analyzed by qRT-PCR for expression levels of VEGF. All values were normalized to GAPDH
mRNA levels in the same samples. Error bars in (B) and (D) indicate SD. ***p < 0.001 by t test.
(E) Schematic overview of the proposed angiogenic mechanism of miR-296. miR-296 is upregulated in glioma endothelial cells and directly inhibits expression of
HGS, thereby allowing the accumulation of growth factor receptors by attenuating their degradation. GF, growth factor; GFR, growth factor receptor.results demonstrate that inhibition of miR-296 affects glioma
angiogenesis in vivo.
In order to establish the clinical relevance of miR-296 regula-
tion in glioma angiogenesis, we performed experiments on hu-
man endothelial cells isolated from tumor tissue obtained from
neurosurgical resections. Endothelial cells were isolated from
blood vessels dissected from six glioma patients (three grade
IV gliomas [highly malignant] and three grade II gliomas [less ma-
lignant]), all of which were highly angiogenic as confirmed by
CD31 immunohistochemical analysis in pathological specimens
(data not shown), as well as from three normal nonneoplastic
human brain samples (Figure 8A). miR-296 expression levels,
determined by qRT-PCR, were elevated in tumor blood vessels
relative to quiescent normal brain vessels (Figure 8B), while
control miR-186 showed no difference in expression levels. We
further examined expression of HGS, PDGFRb, and VEGFR2
proteins in endothelial cells from human nonneoplastic brain
and malignant gliomas. Immunohistochemical staining revealed
that HGS expression was low and PDGFRb and VEGFR2 were
upregulated in angiogenic glioma blood vessels relative to normal
control vessels (Figure 8C). Finally, using qRT-PCR, we deter-
mined mRNA levels of VEGF in endothelial cells isolated from
nonneoplastic human brain and glioma tissues, as well as in
HBMVECs cultured in the presence or absence of U87 glioma
cells. A clear increase in VEGF mRNA was observed in tumor
endothelial cells and in U87-exposed HBMVEC cultures as com-
pared to these controls (Figure 8D), paralleling miR-296 expres-
sion levels. These data suggest that growth factor-induced miR-
296 expression observed in cultured brain endothelial cells
parallels changes in miR-296 levels in angiogenic endothelial cells
in brain tumors in vivo. Furthermore, miR-296 downregulation of
HGS signaling increases functional PDGFRb and VEGFR2 in tu-
mors, which is complemented by increased expression of VEGF.
DISCUSSION
Altogether, our results support a role for miR-296 in promoting
angiogenesis in tumors. We show that VEGF alone is capableCancer Cell 14, 382–393, November 4, 2008 ª2008 Elsevier Inc. 389
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growth factor-supplemented endothelial medium or glioma cells.
This result points out an interesting feedback loop whereby
VEGF induces miR-296 expression, which targets HGS, which
in turn results in increased VEGFR2 and PDGFRb protein levels
and hence increased response to VEGF. In addition, EGF was
also capable of inducing miR-296, suggesting a complex growth
factor-growth factor receptor crosstalk mechanism that combi-
natorially increases miR-296 levels.
miR-296 was identified in a miRNA screen in normal human
brain endothelial cells as being upregulated in response to
exposure to human brain glioma cells in culture. Down- and
upregulation of miR-296 resulted in the inhibition and induction,
respectively, of morphologic characteristics associated with
angiogenesis of human endothelial cells. Sequence-specific
inhibition of miR-296 by intravenous injection of cholesterol-con-
jugated antagomirs resulted in decreased neovascularization of
tumors in mice. Upregulation of miR-296 expression was also
demonstrated in tumor blood vessels isolated from human
glioblastoma tumors. Altogether, these results support a role
for increased miR-296 levels in promoting angiogenesis in tu-
mors, as illustrated in the model in Figure 8E. It is likely that other
endothelial miRNAs have related pro- or antiangiogenic func-
tions. A proangiogenic role for miR-296 was demonstrated for
HBMVECs as well as HUVECs; however, since miRNAs have
multiple targets, miR-296 may also play important roles in other
physiological processes unrelated to angiogenesis. We propose
that in the endothelial context, miR-296 belongs to the family of
‘‘angiomirs.’’ Kuehbacher et al. (2007) have shown that inhibition
of let-7f and miR-27b also affects angiogenesis. Recently, miR-
126 was found to play an important role in developmental angio-
genesis and vascular integrity (Fish et al., 2008; Wang et al.,
2008). We have detected several members of the let-7 family,
as well as miR-27 and miR-126, in HBMVECs (Figure S1). Under
conditions used in our study, these miRNAs appeared to be
downregulated in HBMVECs exposed to glioma cells. Under-
standing functions of these miRNAs and their contribution to
tumor angiogenesis will require further investigation. Thus,
although several miRNAs have been implicated in endothelial
processes in vitro (Chen et al., 2008; Kuehbacher et al., 2007;
Lee et al., 2007; Poliseno et al., 2006; Sua´rez et al., 2007;
Dews et al., 2006) and in vivo (Fish et al., 2008; Wang et al.,
2008), miR-296 plays a functional role in human tumor-induced
angiogenesis in vitro and in vivo.
We have confirmed that the mRNA for HGS is a target for miR-
296. Our data suggest that miR-296 upregulation has a dominant
downtuning effect on HGS expression in angiogenic endothelial
cells, although additional regulatory factors (including miRNAs)
can not be excluded. Since HGS mediates the degradative sort-
ing of PDGFR (Takata et al., 2000) as well as VEGFR (Ewan et al.,
2006) and EGFR (Bache et al., 2003; Stern et al., 2007), it seems
likely that increased levels of these growth factor receptors in
angiogenic blood vessels are due at least in part to the miR-
296 downregulation of HGS expression.
In recent years, a number of oncomirs (tumor-promoting miR-
NAs) and tumor-suppressing miRNAs have been identified for
various types of cancer cells (reviewed in Esquela-Kerscher
and Slack, 2006; Wurdinger and Costa, 2007). However, the de-
livery of inhibitors or precursor/mimics of such miRNAs to cancer390 Cancer Cell 14, 382–393, November 4, 2008 ª2008 Elsevier Incells in order to block tumor growth remains challenging. Tumor
blood vessels offer an attractive additional target for the delivery
of miRNA inhibitors or precursor/mimics in order to reduce tumor
growth. Recent delivery configurations using siRNA-based and
miRNA-inhibiting antagomirs have proved effective for miRNA
manipulation in vivo, and blood vessels are a feasible target for
such molecules in vivo (de Fougerolles et al., 2007; Krutzfeldt
et al., 2005). Several siRNAs can target the vasculature, resulting
in alterations in blood vessel structure and function (Reich et al.,
2003; Shen et al., 2006). These siRNAs are aimed at silencing
single specific mRNA targets but may have off-target side effects
(Jackson et al., 2003). miRNAs such as miR-296, however, can
regulate a broad range of ‘‘natural’’ mRNA targets (Miranda
et al., 2006) and might therefore prove more efficient for fine
tuning cellular switch programs. Our results indicate that miR-
296 is a critical component of the angiogenic process, possibly
in a one-hit/multiple-target fashion (Wurdinger and Costa, 2007),
and provide insights into the role of miRNA regulation of neovas-
cularization. Furthermore, manipulation of angiomir levels may
prove therapeutic in the vast number of diseases in which angio-
genesis is a critical component.
EXPERIMENTAL PROCEDURES
Cells
Human brain microvascular endothelial cells (HBMVECs; Cell Systems,
ACBRI-376) and human umbilical vein endothelial cells (HUVECs; Cambrex)
were cultured in EGM medium (Cambrex) for no more than ten passages.
U87 cells (ATCC; U87 MG) and 293T cells were cultured in DMEM containing
10% FBS and antibiotics. U87-CFP cells were produced by stably transducing
U87 cells with a CMV-controlled cerulean expression cassette using a lentiviral
vector (Rizzo et al., 2004).
Endothelial Cell Isolation
Endothelial cells were isolated from HBMVECs cultured for 24 hr alone or in the
presence of glioma cells using CD31 Endothelial Cell Dynabeads (Dynal
Biotech). Cells were trypsinized, and trypsin was then inactivated using trypsin
neutralization solution (Cambrex). Single-cell suspensions containing 1 3 106
cells were washed once in PBS and resuspended in 1 ml PBS, to which 25 ml of
CD31 Dynabeads was added. The tubes were subjected to slow rotation for
20 min at 4C. Subsequently, the tubes were placed in a magnet for 2 min
and washed three times with 1 ml PBS containing 0.1% BSA. Isolated endo-
thelial cells were plated in EGM medium and analyzed for presence of U87-
CFP contamination using a combination of light and fluorescence microscopy.
Only an occasional sporadic U87-CFP cell was observed, indicating >99.9%
purity of the endothelial cell population. Endothelial cells were also isolated
from blood vessels dissected from three grade IV gliomas and three grade II
gliomas, as well as from normal nonneoplastic human brain. All endothelial
cell isolations from normal human brain and glioma tissue were performed us-
ing CD31 and VE-cadherin magnetic-activated cell sorting (MACS), and >99%
purity of cell isolations was confirmed by UEA-1 binding and 1,10-dioctadecyl-
3,3,30,30-tetramethylindocarbocyanine perchlorate-acetylated low-density li-
poprotein (Ac-Dil LDL) uptake as described previously (Miebach et al., 2006).
RNA Isolation
Total RNA was isolated from endothelial cells passaged fewer than seven
times in culture and primary endothelial cells (passage 0) isolated from normal
brain and glioma tissue. RNA isolation was carried out by adding 600 ml of lysis
buffer from a mirVana miRNA isolation kit (Ambion) to the CD31 bead-bound
cells. The quality and quantity of the RNA were analyzed by photospectrometry
and analytical 15% TBE-UREA gels (Bio-Rad) after ethidium bromide staining.
miRNA Inhibition and Overexpression
For the inhibition of miR-296, 50 nM miR-296 inhibitor oligonucleotide (Am-
bion) or control oligonucleotides were transfected into HBMVECs or HUVECsc.
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pre-miR-296, pre-control-Cy3, or pre-control-1 (Ambion) was transfected into
HBMVECs. After 5 hr, the cells were trypsinized, replated, and cultured in EBM
or EGM until further analysis.
In Vitro Glioma Angiogenesis Assay
HBMVECs or HUVECs (both passaged fewer than seven times) were cultured
on Matrigel (Becton Dickinson) in EBM (Cambrex) in the presence or absence
of U87-CFP cells or EGM (Cambrex). After 24 hr, the cultures were analyzed by
a combination of light and fluorescence microscopy. The experiments were
performed in triplicate, repeated at least twice, and judged in a double-blind
fashion by at least two observers. Three or more random pictures were taken
of each culture using a digital camera system and the software program Meta-
Vue (Molecular Devices), and images were subsequently analyzed for total
tubule length and number of tubule branches using the software program
ImageJ.
In Vitro Migration Scratch Assay
Confluent HBMVECs (passaged fewer than seven times) were transfected with
miR-296 mimics, inhibitors, or control oligonucleotides using Lipofectamine
2000 (Invitrogen). At 5 hr after transfection, a cell scratch spatula was used
to make a scratch in the cell monolayer, after which the cell monolayers
were rinsed and further incubated. Pictures of the scratches were taken using
a digital camera system coupled to a microscope. The cells were incubated for
24 hr, after which pictures were taken again. MetaVue was used to determine
the migration distance (in mm) as the reduction of the width of the open area.
Luciferase miRNA Target Reporter Assay
Total cDNA from HBMVECs was used to isolate the 30UTR of Hgs by PCR us-
ing the forward primer 50HGS TTGACTAGTCCCAGGCCATGCTCACGTCCG
GAGTAACACTAC and the reverse primer 30HGS TTGAAGCTTGAAATACAT
TTTATTATCGCTGTACCATTCTGGGG. After digestion of the PCR product
by SpeI and HindIII, the Hgs 30UTR was cloned into the SpeI and HindIII sites
of the multiple cloning site (MCS) of pMir-Report (Ambion), resulting in pMir-
Report-30HGS. Mutations were introduced in the potential miR-296 114–134
and 352–372 binding sites (Figure 3A). The flanking primers that were used
for the isolation of the Hgs 30UTR from the endothelial cDNA were combined
with primers containing mutated target sequences. For the 50 (pMir-Report-
30HGS-mut114–134, denoted HGS mut1) miR-296 binding site, primers
used were mutP1AF: CAACCTGACTAAAACCCGGAACACCCCAAGCCCACC
TCCCTTGTCCTCAG and mutP2AR: TTCCGGGTTTTAGTCAGGTTGAGAAG
GGACACTACCGGCAGTAGAGGACA. For the downstream (pMir-Report-
30HGS-mut352–372, denoted HGS mut2) miR-296 binding site, primers
used were mutP1BF: CACAATGACACCTCCCCGAGCCTCTGCAGGGGCCT
CTCTCGGCAGCCACA and mutP2BR: GCTCGGGGAGGTGTCATTGTGAC
ACCACAGCCAGCTCACAGTGCGGCCAG. 293T cells were transfected with
the pMir-Report vectors containing the wild-type Hgs and variant 30UTRs,
and at 5 hr after transfection, the cells were transfected again with 50 nM
miR-296 inhibitors (Ambion) or control oligonucleotides (Ambion). After 24 hr,
the cells were lysed and luciferase activity was measured using a luminometer.
A plasmid containing an expression cassette for Renilla luciferase, pRenilla
(Promega), was cotransfected and used to normalize the firefly luciferase
values expressed from the pMir-Report constructs.
Immunofluorescence Staining and Western Blotting
Cell cultures were fixed using PBS containing 4% paraformaldehyde for 15 min
at room temperature (RT) and (for HGS) permeabilized using PBS containing
1% Triton X-100 for 5 min at RT. Nonspecific antibody binding was blocked
by incubating the cells in PBS containing 5% FCS for 30 min at RT. Mouse
monoclonal anti-HGS (1:100, Alexis Biochemicals), anti-PDGFRb (1:50, BD
Biosciences), and anti-VEGFR2 (1:400, Abcam) antibodies were used to
detect HGS, PDGFRb, and VEGFR2, respectively. Donkey anti-mouse-Cy3
(1:600, Jackson Immunolabs) was used as a secondary antibody. Immunoflu-
orescence was analyzed using fluorescence microscopy. Immunohistochem-
ical analysis of CD31 was performed as described previously (Miebach et al.,
2006). For western blotting, cells were grown for 24 hr and lysed by standard
procedure in RIPA buffer containing protease inhibitor cocktail (Roche Diag-
nostics). Protein concentrations of total cell lysates were measured using aCaMicro BCA Protein Assay Kit (Pierce Biotechnology), and 40 mg of tissue cul-
ture lysate per lane was resolved on SDS-PAGE gels (Invitrogen) followed by
immunoblot detection and visualization with ECL western blotting detection
reagents (Pierce Biotechnology). The bands of the western blots were quan-
titated using ImageQuant software (Molecular Dynamics). The intensities
were normalized to anti-b-actin levels and depicted as relative intensities. Im-
munoblotting was performed with the primary antibodies mouse anti-HGS
(1:1000, Alexis Biochemicals), mouse anti-PDGFRb (1:1000, Abcam), mouse
anti-VEGFR2 (1:1000, Abcam), and mouse anti-b-actin (1:5000, Abcam).
In addition, http://www.proteinatlas.org/ was used as a source of immuno-
histochemical analysis for CD31, HGS, PDGFRb, and VEGFR2 protein
expression.
Quantitation of HGS, PDGFRb, and VEGFR2 Expression
in Cells Treated with siRNAs
The expression levels of HGS, PDGFRb, and VEGFR2 were measured as
immunofluorescence intensity per cell. The experiments were performed in
triplicate, repeated at least twice, and judged in a double-blind fashion by at
least two observers. Twenty or more random pictures (one cell per field)
were taken using a Nikon fluorescence microscope system coupled to a digital
camera and analyzed using MetaVue. The values of the HGS, PDGFRb, and
VEGFR2 average intensities were averaged. Error bars denote SD, and t test
was used to determine significant differences.
In Vivo Imaging of Angiogenesis
All experiments on mice were approved by the Subcommittee on Research
Animal Care at Massachusetts General Hospital and were performed in ac-
cordance to their guidelines and regulations. One million U87 cells were
mixed with 50 ml Matrigel (Becton Dickinson) and directly injected subcutane-
ously into the back flanks of nude mice. After 7 days, each mouse was
injected intraocularly with 2 mg of miR-296 antagomirs or mismatch control
antagomirs (100 ml of a 20 mg/ml stock diluted in PBS; Regulus Therapeu-
tics). Four days after injection of antagomirs, 150 ml (2 nmol fluorochrome)
of AngioSense 750 (VisEn Medical) was injected intravenously. One hour
later, coronal fluorescence-mediated tomography (FMT) images were ac-
quired using a continuous wave-type scanner capable of acquiring transillu-
mination, reflectance, and absorption data (VisEn Medical). Prototypes of the
device and reconstruction algorithms, as well as the imaging protocol, have
been described previously (Montet et al., 2005, 2007; Ntziachristos et al.,
2002; Grimm et al., 2005). Mice were also imaged by magnetic resonance
(MR) using a 4.7T small-animal MR scanner (Bruker BioSpin). The imaging
protocol consisted of an axial T1-weighted sequence with the following pa-
rameters: fast spin echo 635/15 ms repetition time/echo time, four averages,
matrix slice 256 3 128, field of view 4.0 3 2.5 cm, slice thickness 1 mm.
Sixteen slices with a slice thickness of 1 mm, field of view of 42 3 24 mm,
and matrix of 128 3 64 were acquired.
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